1.1 Key findings

1.2 Analysis Framework: Frost & Sullivan’s Core Value

1.3 Research Methodology

2.1 Advantages of Using Viral Vectors

2.2 Factors for Selection of Viral Vectors

2.3 Commonly used Viral Vectors

2.4 Suitable Scenario for Viral Vector Manufacturing

3.1Global Viral Vector Market

3.2 Challenges to Overcome

3.3 Increasing competition among viral vector CDMOs

3.4 Technology Adopted to Increase Production Rates

3.5 Mergers & Acquisitions

3.6 Research Collaborations

3.7 Long Term Collaborations

3.8 Recent Innovations at Viral Vector CDMOs

3.9 Digital Workflow Platforms

3.10 Recently Expanded Viral Vector BioManufacturing Units

3.11 Rising Trend of Expansion among Viral Vector CDMOs

3.12 Role of viral vector CDMO in COVID-19 scenario

3.13 Viral vector cdmos provide services for COVID-19 vaccine development

4.1 Innovation Radar of Viral Vector CDMOs

4.2 Summary of the Scoring Methodology

4.3 Advanced Bioscience Labs (ABL) Inc.

4.4 Batavia Bioscience

4.5 Biovian

4.6 CEVEC

4.7 Cobra Biologics

4.8 Oxford Genetics

4.9 Catalent

4.10 Molmed

4.11 Vigene

4.12 ProBiogen

4.13 Oxford Biomedica

4.14 Novasep

5.1 Growth Opportunity 1: R&D Investment

5.2 Growth Opportunity 2: Technology Convergence

5.3 Conclusion

6.1 IP Overview in Viral Vector Manufacturing

6.2 Leading Pharmaceutical Patent Holders

6.3 Top Patents in Viral Vector Modifications

6.4 Viral Vector Patents by Spark Therapeutics

6.5 Relevant Viral Vector Patents by University of Pennsylvania

7.1 Representation of Key Participants Based on Revenue

7.2 Key Industry Contacts

7.2 Key Industry Contacts